Bio Preventive Medicine Corporation (BPM) is a leading company in renal biomarker area and has focused on translating validated and IP-protected biomarkers into diagnostic solutions for unmet clinical needs, especially among the fields of diseases early detection and prevention in diabetes related complications, such as Diabetic Kidney Disease (DKD), Chronic Kidney Disease (CKD) and kidney injury.
Our expertise in DKD and non-proteinuric renal disease led to the development of breakthrough IVD product, CE IVD marked uPTM3-DKD (DNlite-IVD103) ELISA test, which detects a unique post translational modification of a DKD biomarker and identified by large urinary proteomic studies. DNlite-IVD103 is a non-invasive urinary test for effectively predicting/ monitoring the progression of DKD over the 1-2 years that follow.
We are open for any collaboration opportunities. For more information, please visit: https://www.bpmbiotech.com/